John K. Westwick PhD

John K. Westwick, Ph.D. is President and CEO of Resonant Therapeutics, Inc, a biotech start-up creating breakthrough therapies for cancer treatment. He is also a Venture Advisor with Mercury Fund, where he contributes to the assessment of bio/therapeutic opportunities.
Dr. Westwick’s scientific and biotech career spans over 30 years, with a constant focus on defining the cellular mechanisms of cancer, inflammatory and metabolic disease and translating this knowledge into improved therapeutics. Dr. Westwick has contributed to the development of multiple tools and therapeutic programs that are marketed or in development and has published more than 60 scientific articles and patents.
Previously, Dr. Westwick was President & CEO of Odyssey Thera, a privately held company that developed the world's largest collection capability for cell systems biology. Prior to Odyssey, Dr. Westwick held leadership positions at Celgene Corp. and Signal Pharmaceuticals. He holds a B.A. degree in Biology from the University of California at San Diego, and a Ph.D. in Molecular Pathology from the UC San Diego School of Medicine.
His Post-doctoral studies in Medicine and Pharmacology were performed at the University of North Carolina, Chapel Hill School of Medicine, and he was subsequently named the Lineberger Cancer Center Fellow at the UNC Comprehensive Cancer Center. Outside of Resonant and Mercury, Dr. Westwick serves as an advisor to biotech start-ups and on the board of directors of Courier Therapeutics, Inc., Vala Sciences, Inc., and Visionary Pharmaceuticals, Inc.